Check out our most popular compounded medications! Get Started
Our Tramadol HCl 50 mg Oral Slow Release (MEM4) Capsules are expertly crafted to provide patients with consistent and prolonged pain relief. Utilizing Methocel E4M, a sophisticated controlled-release polymer, these capsules are engineered to deliver the active ingredient, Tramadol HCl, slowly over an extended timeframe. This meticulous design ensures a steady therapeutic effect, minimizing the need for frequent dosing and enhancing patient adherence to treatment regimens. Tramadol is an opioid analgesic commonly prescribed for the management of moderate to moderately severe pain in adults, including conditions such as chronic pain, postoperative pain, and pain associated with osteoarthritis.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Tramadol HCl 50 mg Oral Slow Release (MEM4) Capsules are a sophisticated pharmaceutical formulation designed to manage moderate to moderately severe pain over an extended period. These capsules are compounded using Methocel E4M, a high-viscosity grade hydroxypropyl methylcellulose (HPMC), which is a controlled-release polymer that plays a crucial role in the gradual release of tramadol hydrochloride. The incorporation of Methocel E4M into the capsule matrix allows for a consistent and controlled release of the active ingredient, tramadol, into the patient's system, thereby maintaining therapeutic plasma concentrations for an extended duration.
The slow-release mechanism of these capsules is particularly beneficial for patients who require round-the-clock pain management, as it can potentially reduce the need for frequent dosing. This not only enhances patient compliance but also minimizes the risk of peaks and troughs in drug levels, which can lead to side effects or periods of inadequate pain control. Tramadol works by binding to mu-opioid receptors and inhibiting the reuptake of norepinephrine and serotonin in the brain, altering the perception and response to pain.
These capsules are indicated for various disease states that involve chronic pain, such as osteoarthritis, neuropathic pain, and certain chronic musculoskeletal conditions. By providing a sustained analgesic effect, Tramadol HCl 50 mg Oral Slow Release (MEM4) Capsules can improve the quality of life for patients suffering from these conditions. It is important for prescribers to consider the patient's overall pain management plan, potential drug interactions, and individual response to tramadol when prescribing this formulation.
As with any medication, there are potential side effects associated with tramadol, including but not limited to nausea, dizziness, constipation, headache, and somnolence. It is also important to note that tramadol has the potential for abuse, addiction, and misuse, which should be taken into account when prescribing and dispensing this medication. Patients should be monitored for signs of abuse and addiction. Additionally, tramadol should be used with caution in patients with a history of seizures or those taking medications that lower the seizure threshold.
For more detailed information on Tramadol HCl 50 mg Oral Slow Release (MEM4) Capsules, or if you have any questions regarding this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is committed to providing high-quality, patient-specific formulations and is available to assist healthcare providers in optimizing pain management strategies for their patients.
Tramadol HCl is an opioid analgesic used to manage moderate to moderately severe pain. When formulated as a 50 mg Oral Slow Release (MEM4) Capsule with Methocel E4M, tramadol is released gradually over time, which can help maintain a consistent level of pain relief. However, due to its pharmacological properties, tramadol can interact with a variety of medications and substances, which may affect the safety and efficacy of the treatment.
One significant interaction is with central nervous system (CNS) depressants, including other opioids, benzodiazepines, alcohol, anxiolytics, hypnotics, and sedatives. Concurrent use can result in additive CNS depression, leading to increased risk of respiratory depression, profound sedation, coma, or even death. Patients should be closely monitored, and the dosage of one or both agents should be adjusted accordingly.
Tramadol is metabolized by the liver enzyme CYP2D6, and co-administration with CYP2D6 inhibitors, such as fluoxetine, paroxetine, or bupropion, can lead to increased tramadol levels and risk of seizures and serotonin syndrome. Conversely, CYP2D6 inducers like rifampin or St. John's Wort may reduce tramadol's efficacy by increasing its metabolism.
Additionally, tramadol can increase serotonin levels and should be used with caution in combination with other serotonergic drugs, including SSRIs, SNRIs, MAO inhibitors, triptans, and certain tricyclic antidepressants. This can lead to serotonin syndrome, a potentially life-threatening condition. Symptoms include agitation, hallucinations, fever, sweating, shivering, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.
Anticoagulants, such as warfarin, may also interact with tramadol. Tramadol has been reported to affect the INR and prothrombin times in patients taking warfarin, thus close monitoring of INR and adjustment of the warfarin dose may be necessary when tramadol is initiated or discontinued.
Patients with a history of seizures or those taking medications that lower the seizure threshold, such as certain antipsychotics or antidepressants, should be cautious when using tramadol, as it may increase the risk of seizures.
It is important to note that this is not an exhaustive list of all potential drug interactions. Patients should be advised to inform their healthcare provider of all medications, supplements, and herbal products they are taking before starting tramadol therapy. Healthcare providers should review the patient's medication history to identify potential interactions and adjust therapy accordingly to ensure safe and appropriate use of tramadol slow-release capsules.
If you have any questions or require further information regarding drug interactions with Tramadol HCl 50 mg Oral Slow Release (MEM4) Capsules, please do not hesitate to reach out to us at Bayview Pharmacy. Our team is here to provide the necessary support and guidance.
The Tramadol HCl 50 mg Oral Slow Release (MEM4) Capsules are a sophisticated formulation designed to manage pain effectively over an extended period. Tramadol is an opioid analgesic that works by binding to the mu-opioid receptors in the brain, inhibiting the reuptake of serotonin and norepinephrine, which are neurotransmitters associated with pain and mood. This dual mechanism of action allows tramadol to alter the perception of and response to pain, providing relief.
The key to the slow-release feature of these capsules lies in the use of Methocel E4M, a type of hydrophilic polymer known as hypromellose or hydroxypropyl methylcellulose. Methocel E4M swells and forms a gel when it comes into contact with gastric fluids. This gel matrix creates a barrier through which the tramadol is slowly released. The rate of drug release is controlled by the rate at which the gastric fluid penetrates the gel layer and the rate at which the drug diffuses out into the surrounding environment. This controlled-release mechanism ensures a steady level of medication in the bloodstream, which can help maintain pain relief over a longer duration without the peaks and troughs associated with immediate-release formulations.
By using a controlled-release system, patients may experience more consistent pain management, which is particularly beneficial for chronic conditions requiring around-the-clock treatment. This can lead to improved patient compliance, as the need for frequent dosing is reduced. Patients can take the medication less often, which simplifies their medication regimen and can improve their quality of life.
Tramadol slow-release capsules are indicated for the management of moderate to moderately severe chronic pain in adults who require continuous treatment for an extended period. It is important to note that tramadol has the potential for addiction, abuse, and misuse, which can lead to overdose and death. Therefore, it should be prescribed with caution and used in accordance with the established dosing guidelines.
For prescribers, it is crucial to consider the patient's overall pain management plan, potential drug interactions, and the individual's risk factors for opioid addiction or abuse when prescribing tramadol slow-release capsules. Regular monitoring of patients for efficacy, side effects, and signs of misuse is recommended.
If you have any questions or require further information about Tramadol HCl 50 mg Oral Slow Release (MEM4) Capsules and their use in pain management, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide the support and guidance needed to ensure the safe and appropriate use of this medication.
Tramadol HCl 50 mg Oral Slow Release (MEM4) Capsule is a controlled-release medication that contains Tramadol Hydrochloride as its active ingredient. It's formulated with Methocel E4M, a controlled-release polymer, to gradually release the medication over an extended period of time, which helps in providing sustained pain relief.
Methocel E4M is a type of hydrophilic polymer that swells and forms a gel when in contact with gastric fluids, controlling the release rate of Tramadol HCl from the capsule. By doing so, it ensures a slow and extended release of the drug into the system, maintaining a consistent therapeutic effect and minimizing the need for frequent dosing.
The dosing frequency of Tramadol HCl 50 mg Oral Slow Release Capsules is typically less frequent than immediate-release formulations due to its sustained release mechanism. It's important to follow your healthcare provider's instructions regarding dosage, as it may vary depending on individual needs and response to treatment.
No, these capsules are designed for a controlled and prolonged release of medication. As such, they will not provide immediate pain relief but are aimed at offering a consistent and extended analgesic effect to manage chronic pain.
No, crushing or chewing the capsule can interfere with the controlled-release mechanism provided by Methocel E4M, potentially releasing the entire dose at once and increasing the risk of side effects. If you have trouble swallowing pills, consult your healthcare provider for alternatives.
As an opioid analgesic, Tramadol carries a risk of addiction, abuse, and misuse, even at the prescribed dosage. The risk may be lower with a controlled-release formulation, but it's still important to use the medication strictly as prescribed by your healthcare provider.
Possible side effects include dizziness, nausea, constipation, headache, drowsiness, and vomiting. While the controlled-release formulation may reduce the incidence of side effects, it's important to monitor your response and notify your healthcare provider if you experience any adverse effects.
Before taking any new medication, including the Tramadol HCl Oral Slow Release Capsule, you should discuss potential interactions with your healthcare provider. Certain medications may interact with Tramadol and affect how it works or increase the risk of serious side effects.
If you miss a dose, take it as soon as you remember. However, if it's almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not double up to make up for a missed dose without consulting your healthcare provider.
Store the capsules at room temperature, away from direct light, moisture, and heat. Keep the medication out of reach of children and pets, and do not use the capsules past the expiration date indicated on the packaging.
Consuming alcohol while taking Tramadol HCl can increase the risk of respiratory depression, dizziness, and may lead to other harmful side effects. It is generally advised to avoid alcohol while on this medication. Always consult with your healthcare provider for advice on alcohol consumption with opioid analgesics.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
